RxDoctor Payments Data

Matthew Goldinger

Family · Butler, PANPI 1821097171

Payments from drug & device makers

$870in general payments, 2019–2025

Across 10 payments — averaging $86.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$157
  • Davol Inc.$122
  • Medtronic$121
  • Johnson & Johnson$110
  • Sumitomo Pharma America, Inc.$89
  • Axonics, Inc.$85
  • plus $185 from 3 others

What the payments were for

  • Speaking & faculty fees$8510%
  • Food & beverage$78490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$870 in reported general payments places this provider in the 70th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$35,279
Medicare patients
357
Services billed
473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron168$165,404
GemtesaVibegron34$43,291
Methenamine Hippurate106$8,708
Mirabegron ErMirabegron15$7,261
Tamsulosin Hcl499$6,566
Solifenacin Succinate92$4,023
Tolterodine Tartrate ErTolterodine Tartrate12$2,881
Trospium Chloride44$2,637
Trimethoprim38$2,005
Dutasteride71$1,845
Oxybutynin Chloride98$1,801
Oxybutynin Chloride ErOxybutynin Chloride106$1,642
Finasteride128$1,533
Estradiol25$1,242
Alfuzosin Hcl ErAlfuzosin Hcl38$817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$56$165,404168 claims
Sumitomo Pharma America, Inc.Gemtesa$89$43,29134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,717 family providers in Pennsylvania.

Other family in Butler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →